<eFetchResult xmlns="http://www.ncbi.nlm.nih.gov/soap/eutils/efetch_pubmed">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="Publisher">
        <PMID Version="1">22962439</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>9</Month>
            <Day>10</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Sep</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacokinetic and Pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two Phase I trials in patients with advanced solid tumors.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText>PURPOSE: MNRP1685A is a monoclonal antibody to neuropilin-1 (NRP1). We evaluated blood-based pharmacodynamic (PD) biomarkers of MNRP1685A in two Phase I studies to assess exposure/response relationships to inform target dose and regimen selection. EXPERIMENTAL DESIGN: The Phase I studies evaluated escalating doses of MNRP1685A as a single agent or in combination with bevacizumab. Plasma Placental Growth Factor (P1GF), VEGF and circulating NRP1 (cNRP1) were evaluated at multiple time-points using meso-scale discovery (MSD) assays and ELISA, respectively. Plasma PlGF was also measured in a Phase I/II trial of bevacizumab in metastatic breast cancer (AVF0776). The association between PlGF and MNRP1685A dose was described by a sigmoid Emax model. cNRP1 and MNRP1685A PK profiles were described using a two-target quasi-steady state (QSS) model. RESULTS: A dose and time dependent increase in plasma PlGF and cNRP1 was observed in all patients treated with MNRP1685A. PK/PD analysis showed that bevacizumab and MNRP1685A had an additive effect in elevating P1GF. Predictions based on the two-target QSS model showed that the free drug concentration to maintain greater than 90% saturation of membrane NRP1 (mNRP1) and cNRP1 is about 8 mug/mL. CONCLUSIONS: These data show that MNRP1685A inhibits the VEGF pathway in humans as assessed by an increase in plasma PlGF. MNRP1685A appears to enhance bevacizumab-mediated VEGF pathway blockade, as demonstrated by an increase in the magnitude of PlGF elevation when combined with bevacizumab. PK/PD analysis of biomarkers in the Phase I population allowed identification of doses at which apparent maximal pathway modulation was observed.</AbstractText>
            </Abstract>
            <Affiliation>Pharmacokinetics, Pharmacodynamics, Bioanalytical Sciences, Genentech Inc.</Affiliation>
            <AuthorList>
                <Author>
                    <LastName>Xin</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Jessica</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Jenny</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Kinard</LastName>
                    <ForeName>Rashell</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Weekes</LastName>
                    <ForeName>Colin D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author>
                    <LastName>Patnaik</LastName>
                    <ForeName>Amita</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Lorusso</LastName>
                    <ForeName>Patricia M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author>
                    <LastName>Brachmann</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Tong</LastName>
                    <ForeName>Raymond K</ForeName>
                    <Initials>RK</Initials>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Yibing</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Watts</LastName>
                    <ForeName>Ryan</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Bai</LastName>
                    <ForeName>Shuang</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Hegde</LastName>
                    <ForeName>Priti S</ForeName>
                    <Initials>PS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>7</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1078-0432.CCR-12-1652</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1652</ArticleId>
            <ArticleId IdType="pubmed">22962439</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
</eFetchResult>